ライフサイエンスコーパス: zolpidem

1 e affinity of an alpha(1)-selective agonist (zolpidem).

2 is changed to isoleucine are insensitive to zolpidem.

3 neurons, paralleling enhanced sensitivity to zolpidem.

4 eric GABA(A)-R modulators diazepam (DZP) and zolpidem.

5 profiles of etomidate and THIP compared with zolpidem.

6 loreclezole and insensitive to diazepam and zolpidem.

7 ere observed during the repeated exposure to zolpidem.

8 smission in a manner similar to diazepam and zolpidem.

9 ir functionally expressed GABAA receptors to zolpidem.

10 orexant, 10 mg and 20 mg, but diminished for zolpidem.

11 pared with 30% for placebo, and 40% for 10mg zolpidem.

12 ith the ability of single dose detection for zolpidem.

13 when they are treated with the sleeping pill zolpidem.

14 aptic receptors, which were not modulated by zolpidem.

15 itive allosteric modulators, eszopiclone and zolpidem.

16 nsive to diazepam, other benzodiazepines and zolpidem.

17 and frontal brain metabolism in response to zolpidem.

18 owed concentration-dependent potentiation by zolpidem (0.03-100 microM), which was substantially blun

19 n ramelteon (0.63 [0.16-1.10; very low]) and zolpidem (0.60 [0.00-1.20; very low]).

20 clone: OR 0.43 [95% CI 0.20-0.93; very low]; zolpidem: 0.43 [0.19-0.95; very low]); however, zolpidem

21 clone: OR 2.00 [95% CI 1.28-3.13; very low]; zolpidem: 1.79 [1.25-2.50; moderate]); and zopiclone cau

22 GABA(A) receptor alpha1 subunits and reduced zolpidem (100 nM) enhancement of GABA-evoked currents.

23 %, relative to the AHP HW during exposure to zolpidem, 3:4).

24 8%]) relative to placebo (37/75 [49.3%]) and zolpidem (31/73 [42.5%]).

25 ribed), ibuprofen (6.9%), diclofenac (6.3%), zolpidem (4.5%), and lorazepam (3.7%).

26 Zolpidem (5, 10 or 20 mg/kg, i.p.) or vehicle was admini

27 orexant (5 mg, 10 mg, or 20 mg), placebo, or zolpidem (5-10 mg) for 14 days.

28 , and alpha5 subunit-containing GABAARs) and zolpidem (a positive modulator mainly at the alpha1 GABA

29 that enhancing phasic GABA signalling using zolpidem, a Food and Drug Administration (FDA)-approved

30 Infusion of Zolpidem, a GABA(A)alpha1-preferring benzodiazepine-site

31 Zolpidem, a GABAA receptor-positive modulator, is the go

32 uctures of GABA(A) receptors in complex with zolpidem, a positive allosteric modulator and heavily pr

33 Therefore zolpidem, a short-acting GABAAR modulator with selectivi

34 Binding of zolpidem, a systemically active allosteric modulator tha

35 We examined the effects of zolpidem, a widely prescribed nonbenzodiazepine hypnotic

36 Paradoxically, DZP, which, unlike zolpidem, acts at alpha5-containing GABA(A)-Rs, increase

37 receptors in the frontal cortex by systemic zolpidem administration also reduced sleep latency, but

38 le change in cell survival following chronic zolpidem administration in young versus old animals.

39 ase in Delta sleep, suggesting that repeated zolpidem administration might elicit enduring modificati

40 itecture 24 h after cessation of sub-chronic zolpidem administration revealed a decrease in Delta sle

41 Zolpidem administration sharply reduces EEG power and co

42 The analysis shows that following zolpidem administration, changing patterns of coherence

43 Therefore, sub-chronic administration of zolpidem affected lasting modifications in sleep organiz

44 c BZD flunitrazepam with wild-type affinity, zolpidem affinity is decreased approximately 8-fold.

45 ation of pentobarbital, benzodiazepines, and zolpidem all significantly increased the GABA-evoked res

46 In the absence of zolpidem, all subjects show a strong low frequency oscil

47 Compared with natural NREM sleep, zolpidem also decreases the EEG power, an effect that de

48 The imidazopyridine zolpidem (Ambien) is one of the most commonly prescribed

49 Zolpidem (Ambien) is the most widely prescribed "sleepin

50 Using zolpidem (Ambien), a short-acting GABAA agonist hypnotic

51 azole, lorazepam, clonazepam, temazepam, and zolpidem, among others, are primary candidates for drug

52 Zolpidem, an alpha1-preferring benzodiazepine-site agoni

53 Binding of both [3H]zolpidem and [3H]Ro 15-1788 was significantly increased

54 uating or exaggerating allosteric actions of zolpidem and allopregnanolone, respectively.

55 ere relatively insensitive to enhancement by zolpidem and diazepam, and were enhanced by loreclezole

56 The sleep-aids zolpidem and eszopiclone exert their effects by binding

57 arbital as well as other sedative-hypnotics (zolpidem and ethanol) versus wild-type littermates.

58 lpha- and beta-subunit selective modulators, zolpidem and loreclezole, had different effects on IPSCs

59 rketScan database data to describe trends in zolpidem and low-dose trazodone dispensing among adults

60 Zolpidem and THIP significantly increased the amplitudes

61 Zolpidem and trazodone were the most widely prescribed i

62 azolam and the alpha1GABAA preferential PAMS zolpidem and zaleplon reduced accuracy in both procedure

63 Benzodiazepines and 'Z-drugs' (including zolpidem and zopiclone) are GABA(A) receptor (GABA(A)R)

64 dulation of I(GABA) by positive (flurazepam, zolpidem) and negative [3-carbomethoxy-4-ethyl-6,7-dimet

65 intermediate, and high doses of eszopiclone, zolpidem, and DORA-22 were examined after first defining

66 ding pocket on the abilities of eszopiclone, zolpidem, and flurazepam to potentiate I(GABA).

67 res; (2) reduced sensitivity to diazepam and zolpidem, and increased sensitivity to Zn2+ indicate tha

68 currents were robustly enhanced by diazepam, zolpidem, and loreclezole.

69 uring withdrawal from ethanol, diazepam, and zolpidem, and measured consumption of and preference for

70 Treatment of Ndufs4 KO mice with papaverine, zolpidem, and rapamycin-suppressed inflammation, prevent

71 Eszopiclone, zolpidem, and suvorexant improved short-term global and

72 Eszopiclone, zolpidem, and suvorexant may improve short-term global a

73 aphy with the alpha(1) selective ligand, [3H]zolpidem, and the non-selective benzodiazepine site liga

74 e accuracy dose-effect curves for triazolam, zolpidem, and zaleplon increased with box number in the

75 Benzodiazepines, eszopiclone, zolpidem, and zopiclone were more efficacious than melat

76 mine, eszopiclone, lemborexant, seltorexant, zolpidem, and zopiclone were more efficacious than place

77 tudy endpoint, benzodiazepines, eszopiclone, zolpidem, and zopiclone were worse than placebo, doxepin

78 ir samples from drug users, blank hairs, and zolpidem- and zolpidem-D6-soaked hairs were investigated

79 Thus, classic BZDs and zolpidem are likely to have different requirements for h

80 pines, and Z-drugs (zopiclone, zaleplon, and zolpidem) are commonly prescribed medicine classes assoc

81 ected thalamocortical spindles in isolation, zolpidem augmented the temporal coordination between slo

82 econd described a sedative-hypnotic, such as zolpidem, being used for insomnia by a person with good

83 roportion of alpha1 subunit pharmacology, as zolpidem binding affinity is unaltered.

84 92) that is required to confer high-affinity zolpidem binding to GABARs.

85 subunit residues important for high-affinity zolpidem binding.

86 en identified as necessary for high-affinity zolpidem binding.

87 rior collicular seizure parameters or on [3H]zolpidem binding.

88 on produced a localized, 48% decrease in [3H]zolpidem binding.

89 Similar to classic benzodiazepines (BZDs), zolpidem binds at the extracellular N-terminal alpha/gam

90 2I77 mice were made selectively sensitive to zolpidem by genetically swapping the gamma2I77 subunits

91 Zopiclone and zolpidem caused more dropouts due to adverse events than

92 Zolpidem caused significant reductions in wakefulness en

93 rticipants were randomly assigned to receive zolpidem-CR (N=51) or placebo (N=52) (64 women and 39 me

94 Zolpidem-CR had a robust anti-insomnia effect, especiall

95 The C-SSRS indicated that zolpidem-CR had a significant treatment effect (least sq

96 arallel-group randomized controlled trial of zolpidem-CR hypnotic therapy compared with placebo, in c

97 The advantage for zolpidem-CR in reducing suicidal ideation on the C-SSRS

98 f insomnia with controlled-release zolpidem (zolpidem-CR) in suicidal adults with insomnia would prov

99 m drug users, blank hairs, and zolpidem- and zolpidem-D6-soaked hairs were investigated.

100 transient manipulations of airway pressure, zolpidem did not alter pharyngeal muscle responsiveness

101 Zolpidem did not change the apnoea-hypopnoea index versu

102 However, zolpidem differs significantly from classic BZDs in chem

103 ing that these EEG power-reducing effects of zolpidem do not depend on reduced histamine release.

104 Zolpidem docking yielded three equally populated orienta

105 Based on in silico zolpidem docking, three residues within loop F, gamma2Gl

106 change in pharyngeal muscle responsiveness, zolpidem does not alter OSA severity.

107 The sleep induced by zolpidem does not resemble natural sleep because it prod

108 ently stimulated by diazepam (EC(50)=63 nM), zolpidem (EC(50)=85 nM), loreclezole (EC(50)=10.1 microM

109 IC50 = 29 microM), diazepam (EC50 = 158 nM), zolpidem (EC50 = 75 nM), and dimethoxyl-4-ethyl-beta-car

110 In one group, zolpidem enhanced GABA(A) receptor currents but with red

111 Diazepam and zolpidem enhanced GABAR currents with moderate affinity,

112 pha(1)beta(2)gamma(2) GABA(A)Rs and measured zolpidem, eszopiclone, and BZD-site antagonist binding.

113 hole-cell patch-clamp recording of GABA- and zolpidem-evoked responses.

114 ctive, but the alpha1-subunit-selective drug zolpidem exacerbated social deficits.

115 MarketScan; 92.1% of exposed pregnancies had zolpidem exposure.

116 , daridorexant (5, 10, 25, or 50mg), or 10mg zolpidem for 30 days.

117 m, alprazolam, clonazepam, temazepam, and/or zolpidem for current or prior insomnia, at doses of less

118 sh-language article that examined the use of zolpidem for noninsomnia neurologic disorders in humans

119 Zolpidem from consumer hairs, proposed to be strongly bo

120 Zolpidem from external sources could be detected in larg

121 n the seltorexant, 20 mg, group and 1 in the zolpidem group).

122 Compared with ramelteon, eszopiclone and zolpidem had a lower rate of all-cause discontinuations

123 showed good semiquantitative correlation to zolpidem hair concentrations obtained from validated rou

124 Zolpidem has been observed to transiently treat a large

125 sket and bistratified cells were enhanced by zolpidem (HW by 18.4 +/- 6.2 % in 10:15 cells tested), d

126 To the extent that zolpidem improves sleep, these data suggest little or no

127 d picrotoxin and facilitated by diazepam and zolpidem in a concentration-dependent manner.

128 or crossover designs with benzodiazepines or zolpidem in adults younger than 65 years with chronic in

129 The relative potencies of flumazenil and zolpidem in blocking convulsions induced by 9 and DMCM,

130 itivity; even single-dose administrations of zolpidem in single hairs could thus be detected using MA

131 epileptic DGCs; and (3) an inverse effect of zolpidem in some epileptic DGCs demonstrates the heterog

132 4, emerge as being important for stabilizing zolpidem in the BZD binding pocket and probably interact

133 ensing of Z-drugs (zaleplon, eszopiclone, or zolpidem) in the first trimester of pregnancy compared w

134 Zolpidem increased hippocampal ripple density whereas di

135 Zolpidem increased sleep efficiency by 9 +/- 14% (83 +/-

136 The subunit-specific benzodiazepine agonist zolpidem increased the decay time constant of the IPSCs

137 negative component at 100 ms (N100), whereas zolpidem increased the N45 only.

138 P) manipulations indicated that the hypnotic zolpidem increases the arousal threshold and genioglossu

139 Here we show that zolpidem increases the respiratory arousal threshold by

140 Moreover, while eszopiclone- and zolpidem-induced changes were evident in the inactive pe

141 Zolpidem-induced prolongation of mIPSC decay was variabl

142 nit-containing receptors, and which may make zolpidem-induced sleep less optimal.

143 In the second group of epileptic DGCs zolpidem inhibited GABA(A) receptor currents, an effect

144 ceptors were zinc and diazepam sensitive but zolpidem insensitive.

145 alysis of sorted zolpidem-sensitive (ZS) and zolpidem-insensitive (ZI) subpopulations identified ZS c

146 , we deprived alpha1(H101R) mutant mice with zolpidem-insensitive alpha1-containing GABA(A) receptors

147 subunit and exhibited slow (tau(w) = 28 ms), zolpidem-insensitive mIPSCs.

148 ge ethanol even though mPSCs were relatively zolpidem-insensitive.

149 n the GABAA receptor gamma2 subunit gene are zolpidem-insensitive.

150 fic residue interactions and may explain why zolpidem is highly alpha(1)- and gamma(2)-subunit select

151 Activation by zolpidem is proposed to arise from a combination of init

152 In summary, a single night of 10 mg zolpidem is well tolerated and does not cause next-day i

153 In 13 week NT2-N cells, diazepam, zolpidem, loreclezole, and lanthanum had only small effe

154 CI, 0.41-0.64) and in seltorexant, 20 mg, vs zolpidem (LSM ratio, 0.71; 90% CI, 0.57-0.88).

155 Thus, zolpidem may stabilise breathing and reduce OSA severity

156 There were two different patterns of zolpidem modulation of GABA(A) receptor currents in the

157 74), or 20 mg (n = 71); placebo (n = 75); or zolpidem (n = 73).

158 In this paper, we investigate whether zolpidem needs to potentiate only particular GABAergic p

159 rally sleeping rats to detail the effects of zolpidem on network activity during the cardinal oscilla

160 ingly, we sought to determine the effects of zolpidem on OSA severity, upper airway physiology and ne

161 But in contrast to the effect of zolpidem on wild-type mice, the power in the EEG spectra

162 We show using mouse genetics that zolpidem only needs to work on specific parts and cell t

163 to-moderate arousal threshold received 10 mg zolpidem or placebo according to a double-blind, randomi

164 ansiently overcome with sleeping medication (zolpidem) or sedatives (dexmedetomidine; Dex).

165 Since zolpidem potentiation exhibited a substantial age-depend

166 Acute administration of zolpidem produced a suppression of cell proliferation, w

167 In contrast, chronic administration of zolpidem produced little or no effect on proliferation i

168 Eszopiclone and zolpidem produced marked, dose-responsive disruptions in

169 Benzodiazepines and zolpidem produced reliable improvements in commonly meas

170 Zolpidem produces paradoxical recovery of speech, cognit

171 Similarly, Zolpidem prolongation of mIPSC decay rate was significan

172 Zolpidem prolongs IPSCs to decrease sleep latency and in

173 tochondrial optic neuropathy, papaverine and zolpidem provided significant protection from multiple p

174 ower of this method in the cerebellum, where zolpidem rapidly induces significant motor deficits when

175 The benzodiazepine type 1 receptor agonist zolpidem reduced hyperexcitability in both silent period

176 actions, suggesting that unlike eszopiclone, zolpidem relies more on shape recognition of the binding

177 In three diverse patients with known zolpidem responses we identify a distinctive pattern of

178 Zolpidem's enhancement of hippocampal-prefrontal couplin

179 ng as a novel therapeutic strategy, indicate zolpidem's potential to improve recovery, and underscore

180 On night 13, compared with zolpidem, seltorexant, 10 mg and 20 mg, improved LPS by

181 nocytochemical and RT-PCR analysis of sorted zolpidem-sensitive (ZS) and zolpidem-insensitive (ZI) su

182 only synaptic alpha subunit was alpha1, and zolpidem-sensitive mIPSCs had weighted decay time consta

183 When histamine neurons were made selectively zolpidem-sensitive, systemic administration of zolpidem

184 bunit (that is, exchanging Ile77 for Phe77), zolpidem sensitivity can be restored to GABAA receptors

185 iability in the decay (tau(w) = 3-30 ms) and zolpidem sensitivity of mIPSCs.

186 creasing mPSC frequency, decay kinetics, and zolpidem sensitivity that were nearly identical to our e

187 Judging from the zolpidem sensitivity, postsynaptic GABA(A) receptors in

188 m deprived barrels show a marked increase in zolpidem sensitivity.

189 lpidem-sensitive, systemic administration of zolpidem shortened sleep latency and increased sleep tim

190 m 523 PrL and 579 dCA1 neurons revealed that zolpidem significantly enhanced synchronized pauses in c

191 Flurazepam and zolpidem significantly slowed covalent modification of g

192 est tested decontamination protocol, whereas zolpidem-soaked hairs could be cleared almost completely

193 and the benzodiazepine1-selective modulator zolpidem strongly enhanced these IPSPs (45 +/- 28 %, n =

194 On the contrary, the sleep aid zolpidem suppressed norepinephrine oscillations and glym

195 e of the gamma-aminobutyric acid A receptor, zolpidem tartrate presents a potential treatment mechani

196 The commonly used sedative zolpidem tartrate was implicated in 11.5% (95% CI, 9.5%-

197 er administration of the nonorexinergic drug zolpidem that similarly promoted nonrapid eye movement s

198 eveal a basis for the subtype selectivity of zolpidem that underlies its clinical success.

199 Those prescribed zolpidem, the most commonly prescribed medication (80.1%

200 rousal threshold increased by 15 +/- 5% with zolpidem throughout all sleep stages (p = 0.010), wherea

201 he efficacy of sub-chronic administration of zolpidem to alter sleep architecture was enhanced when t

202 Specifically, we administered zolpidem to increase central sigma activity and demonstr

203 To synthesize studies that used zolpidem to treat neurologic disorders.

204 pidem: 0.43 [0.19-0.95; very low]); however, zolpidem was associated with a higher number of dropouts

205 -54 %, 1:1), and the enhancement produced by zolpidem was reduced by flumazenil (-31 +/- 13 %, relati

206 ever, the deprivation-induced sensitivity to zolpidem was reduced in alpha1(H101R) mice.

207 Of the drugs compared here, zolpidem was unique in augmenting coordinated activity w

208 These novel findings indicate that zolpidem was well tolerated and effective in promoting s

209 Papaverine and zolpidem were recently shown to be protective of bioener

210 Effects of zolpidem were wide ranging (eg, improvement on the JFK C

211 st that DORA-22 differs from eszopiclone and zolpidem whereby DORA-22 promotes somnolence without alt

212 Zolpidem, which has no effect on SWA, prolongs VB mIPSCs

213 f two distinct BZ-site ligands, diazepam and zolpidem, which is relatively alpha1-subunit selective.

214 These compounds included zolpidem, which shows preferential binding to GABAA rece

215 reater HICs than LPW mice during ethanol and zolpidem withdrawal, but differed less robustly during d

216 rom pentobarbital also influence ethanol and zolpidem withdrawal, but that diazepam withdrawal may be

217 ct of ethanol on the sensitivity of mPSCs to zolpidem, zinc and 3alpha-hydroxy-5alpha-pregnan-20-one

218 not significantly change mPSC modulation by zolpidem, zinc or 3alpha-OH-DHP.

219 n complex with drugs used to treat insomnia (zolpidem (ZOL) and flurazepam) and postpartum depression

220 odiazepine receptor agonists (BzRAs) such as zolpidem (ZOL) induce sleep through general inhibition o

221 reatment of insomnia with controlled-release zolpidem (zolpidem-CR) in suicidal adults with insomnia

222 Benzodiazepine receptor agonists included zolpidem, zopiclone, and zaleplon.

223 The Z-drugs (zolpidem, zopiclone, zaleplon) are widely used to treat